Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

Paragraf named Business of the Year in Cambridge glory parade VUV Analytics Announces Publication of ASTM D8519-23 Ventyx Biosciences announces initiation of dosing in a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor Ventyx Biosciences announces completion of enrollment of the Phase 2 trial of VTX002 in ulcerative colitis and the Phase 2 trial of VTX958 in plaque psoriasis Novadip Biosciences SA announces first pediatric patient with congenital pseudoarthrosis of the tibia undergoes implantation with NVD-003, an autologous tissue regeneration product, in Phase 1b/2a US/EU clinical trial Trellis Bioscience announces positive interim Phase 1 results for TRL1068, a novel native human monoclonal antibody which reduces bacterial biofilm burden in chronic prosthetic joint infections
Back To News
Our CMO talks solutions and projects
January 31, 2018

Our CMO talks solutions and projects

Aashu Virmani, Fuzzy Logix’ CMO was interviewed recently by independent analyst and industry expert, Ron Powell. He discusses how machine learning applies to anti-money laundering using decision trees, regression and neural nets, explains indexed data management, and gives a glimpse of 2018’s exciting new projects. Listen to the podcast.

The post Our CMO talks solutions and projects appeared first on Fuzzy Logix.

Cookie Policy Privacy Policy